Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: Analysis of multicenter prospective antifungal therapy (PATH) alliance registry

Clinical Infectious Diseases

Volumn 48, Issue 3, 2009, Pages 265-273

  Neofytos, Dionissios ^a,b   Horn, D ^b   Anaissie, E ^c   Steinbach, W ^d   Olyaei, A ^e   Fishman, J ^f   Pfaller, M ^g   Chang, C ⁱ   Webster, K ^j,k   Marr, K ^a,h  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g UNIVERSITY OF IOWA HEALTH CARE   (United States)

^h Fred Hutchinson Cancer Research Center   (United States)

ⁱ Info Spectrum   (Canada)

^j Axiom Real Time Metrics   (Canada)

^k EBM Consulting   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; CALCINEURIN INHIBITOR; CASPOFUNGIN; CORTICOSTEROID DERIVATIVE; ECHINOCANDIN; FLUCONAZOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; VORICONAZOLE;

ADULT; ARTICLE; ARTIFICIAL VENTILATION; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDIASIS; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MUCORMYCOSIS; MULTICENTER STUDY; PRIORITY JOURNAL; RISK FACTOR; SURVIVAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; AMPHOTERICIN B; ANTIFUNGAL AGENTS; ASPERGILLUS; CANDIDA; DEOXYCHOLIC ACID; DRUG COMBINATIONS; FEMALE; FUNGI; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MUCORALES; MYCOSES; NORTH AMERICA; PREVALENCE; PROSPECTIVE STUDIES; PYRIMIDINES; RISK FACTORS; TREATMENT OUTCOME; TRIAZOLES;

EID: 58749083534     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/595846     Document Type: Article

References (18)

1. Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomized, double-blind study. J Infect Dis 1995; 171:1545-52.
2. Marr KA, Seidel K, Slavin MA, et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 2000; 96:2055-61.
3. Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002; 100:4358-66.
4. Kontoyiannis DP, Wessel VC, Bodey GP, Rolston KV. Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis 2000; 30:851-6.
5. Post MJ, Lass-Floerl C, Gastl G, Nachbaur D. Invasive fungal infections in allogeneic and autologous stem cell transplant recipients: a single-center study of 166 transplanted patients. Transpl Infect Dis 2007; 9:189-95.
6. Pagano L, Caira M, Nosari A, et al. Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study - Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. Clin Infect Dis 2007; 45:1161-70.
7. Horn DL, Fishman JA, Steinbach WJ, et al. Presentation of the PATH alliance® registry for prospective data collection and analysis of the epidemiology, therapy, and outcomes of invasive fungal infections. Diagn Microbiol Infect Dis 2007; 59:407-14.
8. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34:7-14.
9. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34:909-17.
10. Cordonnier C, Ribaud P, Herbrecht R, et al. Prognostic factors for death due to invasive aspergillosis after hematopoietic stem cell transplantation: a 1-year retrospective study of consecutive patients at French transplantation centers. Clin Infect Dis 2006; 42:955-63.
11. Upton A, Kirby KA, Carpenter P, Boeckh M, Marr KA. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis 2007; 44:531-40.
12. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347:408-15.
13. Wingard JR, Ribaud P, Schlamm HT, Herbrecht R. Changes in causes of death over time after treatment for invasive aspergillosis. Cancer 2008; 112:2309-12.
14. Fukuda T, Boeckh M, Carter RA, et al. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood 2003; 102:827-33.
15. Crippa F, Holmberg L, Carter RA, et al. Infectious complications after autologous CD34-selected peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2002; 8:281-9.
16. Jantunen E, Salonen J, Juvonen E, et al. Invasive fungal infections in autologous stem cell transplant recipients: a nation-wide study of 1188 transplanted patients. Eur J Haematol 2004; 73:174-8.
17. Grow WB, Moreb JS, Roque D, et al. Late onset of invasive aspergillus infection in bone marrow transplant patients at a university hospital. Bone Marrow Transplant 2002; 29:15-9.
18. Wald A, Leisenring W, van Burik JA, Bowden RA. Epidemiology of aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997; 175:1459-66.